Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study

Rebecca Pedersini, S Monteverdi, G Mazziotti, Vito Amoroso, E Roca, F Maffezzoni, Lucia Vassalli, F Rodella, AM Formenti, S Frara, R Maroldi, A Berruti, Edda Lucia Simoncini, A Giustina

Research output: Contribution to journalArticle

Abstract

Background The impact of long-term adjuvant therapy with aromatase inhibitors (AIs) on vertebral fracture (VF) risk is still unclear. Objective In this cross-sectional study, we explored the prevalence and determinants of VFs in breast cancer (BC) patients before and during AI therapy. Each woman underwent a dual-energy X-ray absorptiometry (DXA) to evaluate bone mineral density (BMD) and identify VFs by a quantitative morphometric approach. Blood samples were collected to measure serum hormone and calcium levels. Results We consecutively included 263 postmenopausal women with hormone receptor-positive early BC. One-hundred-sixty-nine women were AI-naïve, and 94 were AI-treated. AI-treated patients had lower BMD at total hip (p = 0.01) and lumbar spine (p = 0.03), higher serum vitamin D (p 
Original languageEnglish
Pages (from-to)147-152
Number of pages6
JournalBone
Volume97
Issue number16
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study'. Together they form a unique fingerprint.

  • Cite this

    Pedersini, R., Monteverdi, S., Mazziotti, G., Amoroso, V., Roca, E., Maffezzoni, F., Vassalli, L., Rodella, F., Formenti, AM., Frara, S., Maroldi, R., Berruti, A., Simoncini, E. L., & Giustina, A. (2017). Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. Bone, 97(16), 147-152. https://doi.org/10.1016/j.bone.2017.01.013